Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) EPS (Weighted Average and Diluted) (2017 - 2025)

ProQR Therapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.07 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 30.35% to -$0.07 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.07, a 30.35% increase, with the full-year FY2025 number at -$0.47, down 36.17% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.07 in Q4 2025 for ProQR Therapeutics, up from -$34465.6 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for PRQR hit a ceiling of -$0.06 in Q4 2023 and a floor of -$104500.0 in Q1 2025.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$37390.5 across 5 years, with a median of -$33781.8 in 2021.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 100.0% in 2022 and later tumbled 195.75% in 2025.
  • Tracing PRQR's EPS (Weighted Average and Diluted) over 5 years: stood at -$18980.2 in 2021, then soared by 100.0% to -$0.19 in 2022, then surged by 67.17% to -$0.06 in 2023, then plummeted by 75.47% to -$0.11 in 2024, then surged by 30.35% to -$0.07 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for PRQR at -$0.07 in Q4 2025, -$34465.6 in Q3 2025, and -$61242.9 in Q2 2025.